2012 Volume 23 Issue 2 Pages 97-101
Accumulating evidence suggests that the hypofunction via N-methyl-D-aspartate (NMDA) receptors plays a role in the pathophysiology of schizophrenia. Based on the NMDA receptor hypofunction hypothesis of schizophrenia, the novel therapeutic drugs for schizophrenia have been developing as follows : metabotropic glutamate receptor (mGluR2/3) agonists, D-serine plus D-amino acid oxidase (DAO) inhibitors, glycine transporter (GlyT-1) inhibitors. Furthermore, the second antibiotic drug minocycline is also one of the attractive therapeutic drugs for schizophrenia. Here the author would like to discuss the possibility of these therapeutic drugs for schizophrenia.
